Menu Search
Equities

Simcere Pharmaceutical Group Ltd

2096:HKG

Simcere Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.61
  • Today's Change-0.17 / -2.51%
  • Shares traded3.31m
  • 1 Year change-12.22%
  • Beta0.4365
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 5 analysts offering 12 month price targets for Simcere Pharmaceutical Group Ltd have a median target of 8.71, with a high estimate of 11.52 and a low estimate of 7.41. The median estimate represents a 31.77% increase from the last price of 6.61.
High74.2%11.52
Med31.8%8.71
Low12.1%7.41

Dividends in CNY

In 2023, Simcere Pharmaceutical Group Ltd reported a dividend of 0.16 CNY, which represents a 2.89% increase over last year. The 3 analysts covering the company expect dividends of 0.13 CNY for the upcoming fiscal year, a decrease of 20.48%.
Div growth (TTM)2.89%
More ▼

Earnings history & estimates in CNY

Simcere Pharmaceutical Group Ltd reported annual 2023 earnings of 0.270 per share on Mar 20, 2024.
Average growth rate+14.74%
More ▼

Revenue history & estimates in CNY

Simcere Pharmaceutical Group Ltd had revenues for the full year 2023 of 6.61bn. This was 4.57% above the prior year's results.
Average growth rate+13.95%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.